Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
  • You’re registered

Psychedelics in Psychiatry

About This Webinar

An empirical body of empirical research has emerged over the last couple of decades suggesting that the 5-HT2A receptor agonist classic psychedelic compound psilocybin results in positive long term outcomes in both healthy participants and in individuals with psychiatric disorders. This research has been conducted under conditions of substantial preparation, and interpersonal support. Findings have suggested that under such conditions psilocybin leads to increased personality openness in healthy participants, decreased depression and anxiety in cancer patients, and increased biologically-confirmed quit rates in treatment-resistant tobacco cigarette smokers. These findings are consistent with the notion that psychedelic therapy is best thought of as medication-assisted behavioral or psychological therapy, wherein the drug increases behavioral plasticity, providing an experience that can influence future behavior. A vision will be presented suggesting that psychedelics may be leveraged in the treatment of a variety of nominally distinct psychiatric disorders.

Who can view: Everyone
Webinar Price: Free
Featured Presenters
Webinar hosting presenter
Professor of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine
Documents
PDF
Cayman Chemical -Hallucinogen Drug Reference Standards.pdf
Attended (190)
Recommended